0.85
2.86%
-0.025
前日終値:
$0.875
開ける:
$0.88
24時間の取引高:
513.64K
Relative Volume:
0.41
時価総額:
$66.52M
収益:
$101.21M
当期純損益:
$-569.00K
株価収益率:
-42.50
EPS:
-0.02
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
-4.61%
1か月 パフォーマンス:
-17.48%
6か月 パフォーマンス:
-38.41%
1年 パフォーマンス:
-44.44%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
0.85 | 66.52M | 101.21M | -569.00K | -56.88M | -0.02 |
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
2024-05-06 | アップグレード | Jefferies | Hold → Buy |
2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
2021-11-15 | 開始されました | BTIG Research | Buy |
2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
2021-03-29 | 開始されました | JP Morgan | Overweight |
2021-03-23 | アップグレード | Jefferies | Hold → Buy |
2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
2020-03-04 | 開始されました | Barclays | Equal Weight |
2019-11-20 | 開始されました | Guggenheim | Buy |
2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
2019-06-13 | 開始されました | Mizuho | Buy |
2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
2019-03-11 | 開始されました | Barclays | Overweight |
2018-11-26 | 開始されました | Piper Jaffray | Overweight |
2018-10-15 | 開始されました | Goldman | Neutral |
2018-09-13 | 開始されました | H.C. Wainwright | Buy |
2018-06-01 | 開始されました | SunTrust | Buy |
2018-01-05 | 開始されました | Citigroup | Buy |
2017-09-08 | 開始されました | Wedbush | Outperform |
2017-03-27 | 開始されました | H.C. Wainwright | Buy |
2017-03-02 | 開始されました | Instinet | Buy |
2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago - Yahoo Finance
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Sells 1,044,318 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - Yahoo Finance
Short Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4% - MarketBeat
Jane Street Group LLC Decreases Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
Bay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staff - MSN
CytomX stock plunges to 52-week low, touches $0.83 By Investing.com - Investing.com Canada
CytomX stock plunges to 52-week low, touches $0.83 - Investing.com India
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77 - MarketBeat
Bay Area biotech firm once worth $2.3 billion lays off 40% of staff - SFGATE
Geode Capital Management LLC Has $948,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX Therapeutics’ (CTMX) Neutral Rating Reiterated at HC Wainwright - Defense World
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - News & Insights
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - Nasdaq
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CytomX Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
CytomX falls after portfolio shakeup, job cuts - MSN
CytomX Therapeutics' SWOT analysis: oncology biotech's stock faces pivotal year - Investing.com
CytomX stock falls on portfolio shakeup (CTMX:NASDAQ) - Seeking Alpha
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy - Yahoo Finance
CytomX to Cut 40% of Staff as It Updates Pipeline Priorities - BioSpace
CytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC Wainwright - MarketBeat
CytomX refocuses on key cancer drug, extends cash runway - Investing.com India
CTMXCytomX Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
CytomX announces restructuring, staff cuts to extend cash runway - Investing.com
CytomX announces restructuring, staff cuts to extend cash runway By Investing.com - Investing.com South Africa
CytomX refocuses on key cancer drug, extends cash runway By Investing.com - Investing.com Canada
Peninsula biotech to lay off 40% of workforce as it restructures - The Business Journals
CytomX Therapeutics to Cut 40% of Workforce - MarketWatch
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - The Manila Times
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - Zacks Investment Research
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 26.2% in December - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Average Price Target from Analysts - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Position Raised by Fmr LLC - Defense World
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine - MSN
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS - MSN
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry - Simply Wall St
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
CytomX Therapeutics' SWOT analysis: biotech stock's solid tumor focus By Investing.com - Investing.com Canada
Janus Henderson Group PLC Trims Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - MarketBeat
Recent uptick might appease CytomX Therapeutics, Inc. (NASDAQ:CTMX) institutional owners after losing 21% over the past year - Simply Wall St
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Brokerages - Defense World
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
Cytomx Therapeutics Inc (CTMX) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
6,875 |
0 |
110,061 |
Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Sale |
1.23 |
1,984 |
2,439 |
108,077 |
McCarthy Sean A. | CEO |
Aug 20 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
671,749 |
McCarthy Sean A. | CEO |
Aug 20 '24 |
Sale |
1.23 |
13,898 |
17,082 |
657,851 |
McCarthy Sean A. | CEO |
Mar 26 '24 |
Option Exercise |
1.57 |
109,768 |
172,874 |
634,249 |
大文字化:
|
ボリューム (24 時間):